Company intelligence / Profile preview

Crestone, Inc.

Boulder, Colorado, United States

Ownership: Private
Development stage: Phase 2

Overview

Positive Phase 2 clinical trial results for CRS3123 in C. difficile infections showing high clinical cure rates (97% for CRS3123 vs 93% for vancomycin) and very low recurrence rates[4]

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

crs-3123

2 more assets in the full pipeline.

Request access →

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID)

Beyond the preview

Go deeper on Crestone, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crestone, Inc..

Explore the full profile